A new euglobulin clot lysis assay for global fibrinolysis.
Plasma fibrinolytic activity has been measured by the euglobulin clot lysis time (ELT) since the late 1950s. The euglobulin clot lysis assay (ECLA) method has been modified using a computerized kinetic spectrophotometric microtiter plate reader and measures optical density changes of recalcified euglobulin fraction of plasma samples over time. This method has been applied to normal healthy adults, children, pregnant women and newborn infants, which represent physiologic extremes of the ELT. The ECLA method adds measurements of maximum absorbance (Max Abs), area under the curve (AUC) and mean velocity to the standard clot lysis time. The resulting curves are unique to this method and have been analyzed and compared in order to establish normal ranges. Fibrinogen levels, plasminogen activator inhibitor-1 (PAI-1) antigen, PAI-1 activity and thrombin activatable fibrinolytic inhibitor (TAFI) antigen levels were measured in each individual of the four groups. Each protein measured within each study group except TAFI correlated with the lysis time, maximum absorbance and area under the curve. Considering all four groups together, PAI correlates most highly with lysis time, fibrinogen correlates the highest with Max Abs; fibrinogen and PAI-1 antigen have equally high correlations to AUC. Area under the curve is highly correlated with all coagulation parameters measured; the most significant contributor is fibrinogen. These observations are interesting, but at this time, it cannot be said that any of the test parameters are better than lysis time in distinguishing between these normal physiologic states.
Smith
Amy A
AA
Department of Pediatrics, Section of Hematology, University of Colorado Health Sciences Center, Denver, CO USA.
Jacobson
Linda J
LJ
Miller
Brian I
BI
Hathaway
William E
WE
Manco-Johnson
Marilyn J
MJ
D000328:Adult; D019540:Area Under Curve; D001331:Automation; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests / Q000295:instrumentation / Q000379:methods*; D025901:Carboxypeptidase B2 / Q000032:analysis; D002648:Child; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D007231:Infant, Newborn; D007700:Kinetics; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D011247:Pregnancy; D012016:Reference Values; D012712:Serum Globulins; D013057:Spectrum Analysis
D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; D012712:Serum Globulins; D005340:Fibrinogen; D025901:Carboxypeptidase B2